Navigation Links
Elsevier's Biochimica et Biophysica Acta (BBA) Journal Series Adds Open Access Journal: BBA Clinical to its Portfolio
Date:11/13/2013

OXFORD, England, November 13, 2013 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of BBA Clinical, the first full open access journal within the Biochimica et Biophysica Acta (BBA) journal series. BBA Clinical will focus on translating molecular insights into clinical research.

BBA Clinical is a biomedical journal dedicated to publishing research on the molecular basis of human diseases, as well as presenting findings from clinical trials that target biochemical pathways and processes. All articles in BBA Clinical describe, in part or entirely, studies using human patient samples or human cohorts. Clinical areas of particular interest include aging, cancer, cardiovascular-, metabolic-, neurological-, and immunological diseases; the interactions that may occur among these different diseases and conditions; and studies that examine their early or pre-symptomatic states. Cross-sectional and prospective studies from well-established cohorts, and studies involving imaging methodologies, are particularly encouraged for submission.

"The journal provides a new forum for insights concerning the biochemical mechanisms related to diagnosis, progression, and treatment of a wide range of human diseases," said BBA Clinical Executive Editor, Jeffrey N. Keller from Pennington Biomedical Research Center, Baton Rouge, Louisiana. "BBA Clinical will offer not just a useful forum for clinical research today, but it is designed to be a prominent contributor to the larger overall body of clinical advancements far into the future."

"We are very excited about the launch of BBA Clinical," added Dolors Alsina, Executive Publisher at Elsevier. "The journal will build on our long standing track record as one of the leading international journals focusing on molecular aspects in biology and medicine and will break new ground as the clinical complement to BBA Molecular Basis of Disease."

For more information or to submit an article, go to http://www.journals.elsevier.com/bba-clinical

About Open Access Publishing at Elsevier

Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish open access in over 1,600 established peer-reviewed journals as well as 67 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.elsevier.com/openaccess

About Elsevier's Biochimica et Biophysica Acta (BBA) journal portfolio

BBA began publication in 1947. It was the first international journal dedicated to the publication of new findings from the emerging and synergistic fields of biochemistry and biophysics. Since that time, BBA has expanded to meet the needs of scientists focused on understanding the physics, molecular mechanisms, and biomedical underpinnings in diverse fields, including bioenergetics, proteomics, and lipid biology. Today BBA comprises ten different journals, each with unique editors and scope and an average impact factor above 5. The members of the American Library Association recognized BBA's outstanding value in 2009 by electing BBA to the 100 Most Influential Journals in Biology & Medicine over the last 100 years. http://www.elsevier.com/life-sciences/bba

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact

Kristian Wilson
Elsevier
+44-186-584-3817
k.wilson@elsevier.com

 


'/>"/>
SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier Launches New Open Access Journal: Photoacoustics
2. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions OVA1 Test in Presurgical Detection of Early-Stage Ovarian Cancer
3. American Journal of Obstetrics & Gynecology Publishes New Clinical Study Showing Positive Performance of Vermillions Ovarian Cancer Test, OVA1
4. Novation Supplier Diversity Program Recognized in "Best of the Best 2013" by Black EOE Journal
5. Case Report on 14-Year-Old Pediatric Patient Bridged to Transplant with SynCardia Total Artificial Heart Published in the Journal Perfusion
6. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
7. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
8. Elsevier Launches New Open Access Journal in Biomedicine: Journal of Clinical and Translational Endocrinology
9. The Journal of Allergy and Clinical Immunology pubblica i dati sulla termoplastica bronchiale che dimostrano una riduzione sostenuta degli attacchi gravi di asma nellarco di cinque anni
10. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
11. AVTs Customer Medbox, Makes Wall Street Journal MarketWatch Headlines Again
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017  Tarix Orphan LLC today announced that ... Rare Pediatric Disease (RPD) designation for the company,s drug ... Bullosa (RDEB), a rare genetic skin disorder. There are ... limited to supportive care. "The RPD designation ... previously granted by the FDA in this indication," said ...
(Date:1/18/2017)... January 18, 2017 ML ... plans to publish an online presentation tomorrow, January ... sales forecast for 2017. Management reports that the ... record sales performance from its existing operations, and ... entry into the Cannabis sector through a ...
(Date:1/18/2017)...  Robust competition in the private marketplace is ... prices, according to a new study by ... the first to examine the share of prescription medicine ... managers (PBMs), health plans and other stakeholders in the ... first to show what happens when the list price ...
Breaking Medicine Technology:
(Date:1/18/2017)... Agoura Hills, CA (PRWEB) , ... January 18, ... ... risk of dental problems ranging from gum disease to enamel erosion, and those ... from the Massachusetts Department of Public Health, many pregnant women are failing to ...
(Date:1/17/2017)... ... , ... January is National Stalking Awareness Month (NSAM), now in its fourteenth year, ... commit the crime of stalking, a very real danger to many in our community. ... stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads the theme ...
(Date:1/17/2017)... ... January 17, 2017 , ... Gym Source, America’s leading retailer of premium ... South Dixie Hwy in Miami, FL. , “We are elated to be opening this ... in-store concept is designed to give clients a seamless and motivating shopping experience.” , ...
(Date:1/17/2017)... Chicago, Illinois (PRWEB) , ... January 17, 2017 , ... ... Antonio Breast Cancer Symposium (SABCS) or those who desire a more intimate review and ... Antonio: Breast Cancer – Bench to Bedside—is being offered by Imedex on February 4, ...
(Date:1/17/2017)... AZ (PRWEB) , ... January 17, 2017 , ... ... and improved supplement, Healthful-Flex. , The company, owned and operated by Ed ... public at a reasonable price with the highest level of customer service. Healthful ...
Breaking Medicine News(10 mins):